RSV is a highly contagious virus that spreads widely during the cold and flu season. The virus tore through populations of young children and older adults who...
The FDA is requiring GSK to conduct a postmarketing study to assess the signals of serious risks for Guillain-Barré syndrome and ADEM. The company also has committed to assessThe hunt for an RSV vaccine has been ongoing since the 1960s, when an early version crashed and burned inThat earlier vaccine caused a phenomenon called antibody-dependent enhancement, where the antibodies produced by a vaccine actually make a virus more virulent and harmful. Two children died in that clinical trial.
But in the early 2010s, U.S. National Institutes of Health researchers figured out that the F protein which RSV uses to bind with a human cell — much like COVID's spike protein — actually changes shape after it forms that connection. To create a protective immune response, an RSV vaccine would need to target the F protein's pre-infection shape, the researchers reported. Targeting the post-infection shape would either produce no protection or make an infection even worse.
This breakthrough prompted a race among Pfizer, GSK and other pharmaceutical companies to craft a safe and effective RSV vaccine.Copyright © 2022 HealthDay. All rights reserved.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
FDA approves GSK's RSV vaccine for older adults, world's first shot against virusThe FDA's approval is a victory for GSK in a race against Pfizer and Moderna to bring a shot that targets respiratory syncytial virus to the market.
Les mer »
FDA approves first RSV vaccine to protect older adultsUp to 10,000 deaths and 160,000 hospitalizations a year are caused by RSV.
Les mer »
FDA approves world’s first RSV vaccine, a shot for older adultsIn a late-stage clinical trial, the single-dose shot lowered the risk of symptomatic illness by 83% and of severe illness by 94%.
Les mer »
FDA Approves World’s First RSV Vaccine for Adults 60 and OlderResearchers first began attempting to develop a vaccine for respiratory syncytial virus, which is of particular danger to older people and infants, around 60 years ago.
Les mer »
FDA approves first RSV vaccine for adults 60 and olderThe FDA has approved the first-ever vaccine for respiratory syncytial virus, better known as RSV. The vaccine, Arexvy, made by the company GSK, is designed to be administered by a single shot to adults 60 and over.
Les mer »
FDA Approves First RSV Vaccine for Older AdultsThis is the first approved RSV vaccine in the United States, and the world’s first vaccine for older adults.
Les mer »